TY  - JOUR
AU  - Talhouk, Aline
AU  - George, Joshy
AU  - Wang, Chen
AU  - Budden, Timothy
AU  - Tan, Tuan Zea
AU  - Chiu, Derek S
AU  - Kommoss, Stefan
AU  - Leong, Huei San
AU  - Chen, Stephanie
AU  - Intermaggio, Maria P
AU  - Gilks, Blake
AU  - Nazeran, Tayyebeh Mehrane
AU  - Volchek, Mila
AU  - Elatre, Wafaa
AU  - Bentley, Rex C
AU  - Senz, Janine
AU  - Lum, Amy
AU  - Chow, Veronica
AU  - Sudderuddin, Hanwei
AU  - Mackenzie, Robertson
AU  - Leung, Samuel
AU  - Liu, Geyi
AU  - Johnson, Dustin
AU  - Chen, Billy
AU  - Ovarian Cancer Study, Australian
AU  - Alsop, Jennifer
AU  - Banerjee, Susana
AU  - Behrens, Sabine
AU  - Bodelon, Clara
AU  - Brand, Alison H
AU  - Brinton, Louise A
AU  - Carney, Michael E
AU  - Chiew, Yoke-Eng
AU  - Cushing-Haugen, Kara L
AU  - Cybulski, Cezary
AU  - Ennis, Darren
AU  - Fereday, Sian
AU  - Turzanski-Fortner, Renée
AU  - García-Donás, Jesus
AU  - Gentry-Maharaj, Aleksandra
AU  - Glasspool, Rosalind
AU  - Goranova, Teodora
AU  - Greene, Casey S
AU  - Haluska, Paul
AU  - Harris, Holly R
AU  - Hendley, Joy
AU  - Hernandez, Brenda Y
AU  - Herpel, Esther
AU  - Jimenez-Linan, Mercedes
AU  - Karpinskyj, Chloe
AU  - Kaufmann, Scott Harold
AU  - Keeney, Gary
AU  - Kennedy, Catherine J
AU  - Köbel, Martin
AU  - Koziak, Jennifer
AU  - Larson, Melissa C
AU  - Lester, Jenny
AU  - Lewsley, Liz-Anne
AU  - Lissowska, Jolanta
AU  - Lubiński, Jan
AU  - Luk, Hugh
AU  - Macintyre, Geoff
AU  - Mahner, Sven
AU  - McNeish, Iain A
AU  - Menkiszak, Janusz
AU  - Nevins, Nikilyn
AU  - Osorio, Ana
AU  - Oszurek, Oleg
AU  - Palacios, Jose
AU  - Hinsley, Samantha
AU  - Pearce, Celeste L
AU  - Pike, Malcolm C
AU  - Piskorz, Anna
AU  - Ray-Coquard, Isabelle
AU  - Rhenius, Valerie
AU  - Rodríguez-Antona, Cristina
AU  - Sharma, Raghwa
AU  - Sherman, Mark E
AU  - Silva, Dilrini
AU  - Singh, Naveena
AU  - Sinn, Hans-Peter
AU  - Slamon, Dennis J
AU  - Song, Honglin
AU  - Steed, Helen
AU  - Stronach, Euan A
AU  - Thompson, Pamela J
AU  - Tołoczko-Grabarek, Aleksandra
AU  - Trabert, Britton
AU  - Traficante, Nadia
AU  - Tseng, Chiu-Chen
AU  - Widschwendter, Martin
AU  - Wilkens, Lynne R
AU  - Winham, Stacey J
AU  - Winterhoff, Boris J
AU  - Beeghly-Fadiel, Alicia
AU  - Benitez, Javier
AU  - Berchuck, Andrew
AU  - Brenton, James D
AU  - Brown, Robert
AU  - Chang-Claude, Jenny
AU  - Chenevix-Trench, Georgia
AU  - DeFazio, Anna
AU  - Fasching, Peter A
AU  - Garcia, Maria J
AU  - Gayther, Simon A
AU  - Goodman, Marc T
AU  - Gronwald, Jacek
AU  - Henderson, Michelle J
AU  - Karlan, Beth Y
AU  - Kelemen, Linda E
AU  - Menon, Usha
AU  - Orsulic, Sandra
AU  - Pharoah, Paul D P
AU  - Wentzensen, Nicolas
AU  - Wu, Anna H
AU  - Shildkraut, Joellen
AU  - Rossing, Mary Anne
AU  - Konecny, Gottfried E
AU  - Huntsman, David G
AU  - Huang, Ruby Yun-Ju
AU  - Goode, Ellen L
AU  - Ramus, Susan J
AU  - Doherty, Jennifer A
AU  - Bowtell, David D L
AU  - Anglesio, Michael S
TI  - Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE).
JO  - Clinical cancer research
VL  - 26
IS  - 20
SN  - 1557-3265
CY  - Philadelphia, Pa. [u.a.]
PB  - AACR
M1  - DKFZ-2020-01159
SP  - 5411-5423
PY  - 2020
N1  - 2020 Oct 15;26(20):5411-5423
AB  - Gene-expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by non-standardized methods which are not applicable in a clinical setting. We sought to generate a clinical-grade minimal gene-set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features.Adopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene-expression data from 1650 tumors. We applied resulting models to NanoString data on 3829 HGSOCs from the Ovarian Tumor Tissue Analysis Consortium. We further developed, confirmed, and validated a reduced, minimal gene-set predictor, with methods suitable for a single patient setting.Gene-expression data was used to derive the Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor infiltrating lymphocytes, and outcome. The locked-down clinical-grade PrOTYPE test includes a model with 55 genes that predicted gene-expression subtype with >95
LB  - PUB:(DE-HGF)16
C6  - pmid:32554541
DO  - DOI:10.1158/1078-0432.CCR-20-0103
UR  - https://inrepo02.dkfz.de/record/156842
ER  -